Aspen Neuroscience’s David Tastad, PhD, Presented at the Annual Society for Neuroscience Meeting

Aspen Neuroscience’s David Tastad, PhD, presented the poster “Dopamine Neuron Regulation,” at the annual Society for Neuroscience (SFN) meeting on Sunday, November 13th. The presentation explored functional characterization of GBA1 mutations in iPSC-derived midbrain dopaminergic neurons. 

“There was a great turnout at David’s poster at SFN 2022, a session packed with invigorating and collaborative discussions, independent scientific validation and appreciation of our iPSC platform. Many walked away with a better understanding of Aspen’s commitment to developing iPSC-derived cell therapy to address diseases with high unmet medical need, beginning with autologous neuron replacement treatment for both idiopathic and genetic forms of Parkinson’s disease,” said Aspen Neuroscience’s Chief Scientific Officer, Xiaokui Zhang, PhD.  

SFN’s annual conference is held each year for scientists from around the world to congregate to discover new ideas, share their research, and experience the best the field has to offer. 


Please note that we at Aspen Neuroscience do not make determinations on who would be eligible for participation in clinical trials, and we do not offer tours of our laboratory. At this time, our therapy has not yet been used in humans and clinical trials have not begun.